Molecular mechanisms of docetaxel resistance in prostate cancer.

Prostate cancer biomarker docetaxel drug resistant cancer

Journal

Cancer drug resistance (Alhambra, Calif.)

ISSN: 2578-532X

Titre abrégé: Cancer Drug Resist

Pays: United States

ID NLM: 101738710

Informations de publication

Date de publication:
2020

Historique:

received: 27 05 2020

revised: 28 06 2020

accepted: 07 07 2020

entrez: 18 5 2022

pubmed: 21 8 2020

medline: 21 8 2020

Statut: epublish

Résumé

Docetaxel (DTX) chemotherapy offers excellent initial response and confers significant survival benefit in patients with castration-resistant prostate cancer (CRPC). However, the clinical utility of DTX is compromised when primary and acquired resistance are encountered. Therefore, a more thorough understanding of DTX resistance mechanisms may potentially improve survival in patients with CRPC. This review focuses on DTX and discusses its mechanisms of resistance. We outline the involvement of tubulin alterations, androgen receptor (AR) signaling/AR variants, ERG rearrangements, drug efflux/influx, cancer stem cells, centrosome clustering, and phosphoinositide 3-kinase/AKT signaling in mediating DTX resistance. Furthermore, potential biomarkers for DTX treatment and therapeutic strategies to circumvent DTX resistance are reviewed.

Identifiants

DOI: 10.20517/cdr.2020.37 PMID: 35582222 PMC: PMC8992564

pubmed: 35582222

doi: 10.20517/cdr.2020.37

pmc: PMC8992564

doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

676-685

Informations de copyright

Déclaration de conflit d'intérêts

All authors declared that there are no conflicts of interest.

Références

Acta Pharm Sin B. 2018 Jul;8(4):518-529

pubmed: 30109177

Cells. 2020 Jan 14;9(1):

pubmed: 31947623

Mol Cancer Ther. 2012 Apr;11(4):873-87

pubmed: 22294718

J Membr Biol. 2009 Sep;231(1):1-10

pubmed: 19806386

Br J Cancer. 2016 Sep 6;115(6):674-81

pubmed: 27537383

PLoS One. 2011;6(5):e20372

pubmed: 21625523

Br J Cancer. 2017 Apr 25;116(9):1186-1194

pubmed: 28334734

Eur Urol. 2018 Sep;74(3):283-291

pubmed: 29500065

Curr Cancer Drug Targets. 2014;14(1):79-90

pubmed: 24245693

Am J Pathol. 2014 Mar;184(3):609-17

pubmed: 24378408

J Clin Oncol. 2018 Apr 10;36(11):1080-1087

pubmed: 29384722

Mol Cell Biochem. 2014 Aug;393(1-2):265-70

pubmed: 24782036

Int J Mol Sci. 2017 Aug 09;18(8):

pubmed: 28792473

Mol Cancer Ther. 2013 May;12(5):555-66

pubmed: 23635655

Eur Urol. 2017 Apr;71(4):630-642

pubmed: 27591931

Microbiol Mol Biol Rev. 2008 Jun;72(2):317-64, table of contents

pubmed: 18535149

Int J Cancer. 2019 Oct 1;145(7):1970-1981

pubmed: 30807643

Cancer Cell. 2011 May 17;19(5):664-78

pubmed: 21575865

Mol Cancer. 2019 Feb 19;18(1):26

pubmed: 30782187

PLoS Genet. 2016 Jul 18;12(7):e1006162

pubmed: 27428049

Future Oncol. 2017 Feb;13(4):369-379

pubmed: 27712093

Cells. 2019 Apr 23;8(4):

pubmed: 31018586

Clin Cancer Res. 2019 Mar 15;25(6):1880-1888

pubmed: 30301829

Nanomedicine. 2020 Jul;27:102192

pubmed: 32229215

Cancer Cell. 2012 Sep 11;22(3):373-88

pubmed: 22975379

Cold Spring Harb Perspect Biol. 2018 Jun 1;10(6):

pubmed: 29858272

Eur Urol. 2015 Mar;67(3):470-9

pubmed: 25306226

Oncotarget. 2015 Feb 28;6(6):3887-903

pubmed: 25682877

Clin Genitourin Cancer. 2008 Sep;6(2):103-9

pubmed: 18824433

Int J Mol Sci. 2019 Aug 13;20(16):

pubmed: 31412591

Cancer Biol Ther. 2005 Aug;4(8):815-8

pubmed: 16210916

J Clin Invest. 2020 Jun 1;130(6):3287-3298

pubmed: 32478682

Res Rep Urol. 2017 May 08;9:71-77

pubmed: 28507979

Clin Cancer Res. 2002 Apr;8(4):1168-71

pubmed: 11948129

Mol Cancer Ther. 2020 Feb;19(2):364-374

pubmed: 31712394

Proc Natl Acad Sci U S A. 2016 May 31;113(22):6259-64

pubmed: 27185910

Mol Cancer Ther. 2007 Mar;6(3):967-78

pubmed: 17363490

J Clin Med. 2019 Feb 09;8(2):

pubmed: 30744126

Stem Cells. 2018 Oct;36(10):1457-1474

pubmed: 29845679

Genes Dev. 2008 Aug 15;22(16):2189-203

pubmed: 18662975

Cancer Res. 2010 Jun 15;70(12):5163-73

pubmed: 20516116

Pflugers Arch. 2004 Feb;447(5):653-65

pubmed: 14579113

Mol Cancer Ther. 2014 May;13(5):1270-84

pubmed: 24659820

Int J Oncol. 2014 Sep;45(3):985-94

pubmed: 24990514

Prostate. 2009 Oct 1;69(14):1579-85

pubmed: 19575420

J Clin Oncol. 2017 Oct 1;35(28):3181-3188

pubmed: 28632486

N Engl J Med. 2004 Oct 7;351(15):1513-20

pubmed: 15470214

Cancer Res. 2005 Dec 1;65(23):10946-51

pubmed: 16322242

Cancer Cell. 2011 May 17;19(5):575-86

pubmed: 21575859

Cells. 2019 Jul 08;8(7):

pubmed: 31288377

J Urol. 2011 Jun;185(6):2376-81

pubmed: 21511293

Prostate. 2020 Jan;80(1):65-73

pubmed: 31614005

Nat Rev Cancer. 2012 Jul 24;12(8):527-39

pubmed: 22825217

Eur Urol. 2016 Nov;70(5):709-713

pubmed: 26948395

Trends Pharmacol Sci. 2016 Jun;37(6):451-462

pubmed: 27068431

Mol Cancer Ther. 2010 Jun;9(6):1730-9

pubmed: 20515952

Nat Rev Urol. 2020 May;17(5):292-307

pubmed: 32203305

Cancer Res. 2011 Sep 15;71(18):6019-29

pubmed: 21799031

J Cell Biol. 1987 Oct;105(4):1707-20

pubmed: 3312237

J Urol. 2015 Oct;194(4):966-71

pubmed: 25896555

Mol Cancer Ther. 2017 Oct;16(10):2257-2266

pubmed: 28698198

Eur Urol. 2017 Feb;71(2):168-171

pubmed: 27522164

Anticancer Drugs. 2018 Oct;29(9):871-879

pubmed: 29944470

Biol Res. 2012;45(3):297-305

pubmed: 23283439

J Urol. 2014 Jan;191(1):227-34

pubmed: 23954373

N Engl J Med. 2004 Oct 7;351(15):1502-12

pubmed: 15470213

Clin Cancer Res. 2008 Jul 15;14(14):4543-9

pubmed: 18628469

J Clin Med. 2018 Nov 16;7(11):

pubmed: 30453546

Expert Rev Mol Diagn. 2020 Feb;20(2):195-205

pubmed: 31986925

Cancer Res. 2009 Nov 1;69(21):8386-94

pubmed: 19826044

J Clin Oncol. 2014 Apr 10;32(11):1136-42

pubmed: 24616308

Invest New Drugs. 2017 Oct;35(5):599-607

pubmed: 28144789

Cancer Sci. 2018 Oct;109(10):3224-3234

pubmed: 30051622

Nat Commun. 2014 Nov 25;5:5548

pubmed: 25420520

Cancer Res. 2010 Nov 15;70(22):9253-64

pubmed: 21045157

Am J Transl Res. 2010 Mar 15;2(2):135-44

pubmed: 20407603

Oncotarget. 2015 Sep 15;6(27):23358-71

pubmed: 26160840

Lancet. 2016 Mar 19;387(10024):1163-77

pubmed: 26719232

Nature. 2005 May 5;435(7038):114-8

pubmed: 15875026

Cancer Res. 2012 Jul 15;72(14):3457-62

pubmed: 22710436

PLoS One. 2019 Oct 28;14(10):e0222510

pubmed: 31658275

Proc Natl Acad Sci U S A. 1975 May;72(5):1858-62

pubmed: 1057175

Eur Urol. 2019 Mar;75(3):368-373

pubmed: 30773204

Science. 2005 Oct 28;310(5748):644-8

pubmed: 16254181

Cancer Lett. 2018 Aug 28;430:25-33

pubmed: 29775627

Invest New Drugs. 2003 Aug;21(3):259-68

pubmed: 14578676

Adv Cancer Res. 2015;127:123-58

pubmed: 26093899

Stem Cells. 2009 Sep;27(9):2220-8

pubmed: 19544409

Cell. 2003 Feb 21;112(4):467-80

pubmed: 12600311

JAMA Oncol. 2015 Aug;1(5):582-91

pubmed: 26181238

Urol Oncol. 2015 Sep;33(9):385.e15-20

pubmed: 26027763

Mol Cancer Ther. 2010 Mar;9(3):617-30

pubmed: 20179163

Oncotarget. 2017 Oct 9;8(55):94259-94270

pubmed: 29212226

Cancer Res. 2012 Sep 15;72(18):4611-5

pubmed: 22987486

Prostate. 2020 Feb;80(3):267-273

pubmed: 31834633

Prostate. 2016 Jul;76(10):927-36

pubmed: 26997363

CA Cancer J Clin. 2018 Nov;68(6):394-424

pubmed: 30207593

Prostate Cancer Prostatic Dis. 2019 Dec;22(4):560-568

pubmed: 30890759

Nat Rev Urol. 2017 Feb;14(2):90-97

pubmed: 27872478

Prostate. 2011 Dec;71(16):1810-7

pubmed: 21480311

Urol Oncol. 2017 Jan;35(1):31.e13-31.e20

pubmed: 27665358

Prostate. 2009 Sep 15;69(13):1448-59

pubmed: 19496068

Cell Biol Int. 2010 Jan 25;34(2):177-84

pubmed: 19947927

Cells. 2019 Mar 30;8(4):

pubmed: 30935014

Clin Cancer Res. 2015 Oct 15;21(20):4619-29

pubmed: 26202948

Mol Cancer Ther. 2018 Oct;17(10):2197-2205

pubmed: 29891490